Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2013

Qiagen Snaps Up Ingenuity for $105M

  • Qiagen has acquired Ingenuity Systems, provider of software solutions for the analysis and interpretation of genomic data, in a $105 million cash deal. Through this acquisition, Qiagen inherits Ingenuity’s portfolio of products derived from its Knowledge Base initiative—a 14-year effort to curate, model, and structure biomedical data, including genomic variations implicated in disease,computationally—including Ingenuity Pathways Analysis™, Ingenuity Variant Analysis™, and Ingenuity iReport™.

    According to Ingenuity, the company’s “Knowledge Base and software applications enable users to accurately interpret the meaning of increasingly large amounts of biological data to better guide scientific experiments and medical treatment decisions.”

    In a statement, Peer Schatz, Qiagen CEO said that “the interpretation of biological information is becoming a cornerstone of Qiagen's ecosystem of Sample & Assay Technologies for molecular testing—both in life sciences research and in diagnostics.” Speaking of the acquisition, he added: “We are looking forward to expanding the seamless integration of leading biomedical information solutions into our full range of molecular testing solutions, thereby providing our customers a unique experience from sample to interpreted result and recommendations for next steps.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »